Quantcast

Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) – A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children

February 26, 2009

RALEIGH, N.C., Feb. 26 /PRNewswire/ — Arbor Pharmaceuticals, a specialty
pharmaceutical company focused exclusively on pediatric medicine, announced
today that the company has launched XYLAREX – a first-in-class nonantibiotic
for the dietary management of recurrent acute otitis media (middle ear
infections). XYLAREX is a novel oral solution intended to be administered
daily to reduce the number of ear infections children experience. The primary
ingredient in XYLAREX has also been shown to reduce the amount of antibiotics
prescribed to children affected by middle ear infections. XYLAREX can be
administered to children as young as six months of age.

Acute Otitis Media (AOM) is the most common bacterial illness of childhood
and the primary reason antibiotics are prescribed for children in the U.S.
Recurrent AOM affects millions of U.S. children each year, and children
suffering from repeated, painful ear infections are frequently exposed to
numerous courses of antibiotics at a young age. With repeated antibiotic
exposure there is an increased risk of developing bacterial resistance, which
the Centers for Disease Control and Prevention (CDC) call one of the world’s
most pressing health concerns.

“Until now there have been limited options for managing children with
recurrent acute otitis media. Pediatricians and otolaryngologists alike see
many children with recurrent ear infections who have been subjected to
countless antibiotic courses and – in severe cases – may require ear tube
placement to alleviate symptoms. Parents and clinicians are looking for new
options for these children. A novel, non-drug product like XYLAREX is an
important new option for managing children with recurrent AOM in order to
reduce their infections and decrease their need for antibiotics,” says Mark
Mehle
, M.D., a practicing ear, nose, and throat physician in Cleveland, Ohio.

According to Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals,
“XYLAREX is a very important product as it represents a first-in-class
non-drug therapy with the potential to positively impact the lives of millions
of children suffering from recurrent ear infections. Arbor is firmly
dedicated to health of children, and XYLAREX will be a significant addition
for the management of common ear infections.”

XYLAREX is available by prescription and can be obtained from retail
pharmacies across the U.S. XYLAREX is being introduced to U.S. pediatricians
by Arbor Pharmaceuticals’ specialty sales force. XYLAREX is Arbor
Pharmaceuticals’ third product introduction since the company initiated
commercial operations less than two years ago.

About Arbor Pharmaceuticals

Arbor Pharmaceuticals is a Raleigh, North Carolina-based specialty
pharmaceutical company focused exclusively on the growing pediatric market.
The company intends to become the leading pediatrics-focused pharmaceutical
company by actively licensing, developing and commercializing late-stage
products for significant pediatric conditions. The company currently focuses
on nonantibiotic products for the treatment of various ear infections
including ZINOTIC(R) for acute otitis externa and NEOTIC(R) for acute otitis
media. XYLAREX is the latest addition to the Arbor Pharmaceuticals product
portfolio and is indicated for the dietary management of recurrent acute
otitis media.

To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or
send email inquiries to info@arborpharma.com.

SOURCE Arbor Pharmaceuticals


Source: newswire



comments powered by Disqus